文献速递临床试验与 GCP流行病学与生物统计真实世界研究与卫生经济

太阳能供氧治疗乌干达低氧血症儿童:阶梯楔形整群随机对照试验

Solar-powered O2 delivery for the treatment of children with hypoxaemia in Uganda: a stepped-wedge, cluster randomised controlled trial.
PubMed 文献 · Lancet · 2024-02-14

在乌干达20家农村卫生机构开展实用型全国性阶梯楔形整群随机对照试验,序贯安装太阳能供氧系统。纳入2405名5岁以下低氧血症患儿分析,48小时死亡率从随机化前的5.1%降至随机化后的2.9%(校正OR 0.50,95%CI 0.27-0.91,p=0.023),氧疗使用率从50.2%升至98.8%。

要点

  • 太阳能供氧系统序贯安装后,低氧血症患儿48小时死亡率较安装前降低。
  • 校正OR 0.50(95%CI 0.27-0.91,p=0.023),相对风险降低48.7%(95%CI 8.5-71.5)。
  • 每挽救1例生命需治疗45例(95%CI 28-230),氧疗使用率从50.2%升至98.8%。

核心结论

  • 该阶梯楔形整群随机对照试验显示,通过太阳能供氧改善氧可及性可降低低氧血症患儿死亡率。
  • 作者认为本研究可作为在中低收入国家推广太阳能供氧、应对氧不安全问题的模式。

研究设计与样本

  • 实用型、全国性、阶梯楔形整群随机对照试验,在乌干达20家农村卫生机构序贯安装太阳能供氧系统(光伏电池、电池组和氧浓缩器)。
  • 纳入标准为提供儿科住院服务的地区医院或四级卫生中心、儿科病房补充氧不可用或不可靠、有足够空间安装太阳能电池板电池组和电线。
  • 纳入5岁以下因低氧血症和呼吸体征入院的儿童;主要结局为检测到低氧血症后48小时内死亡。
  • 统计分析采用线性混合效应逻辑回归模型,以机构为随机效应、日历时间为固定效应;试验注册号NCT03851783。
  • 2019年6月28日至2021年11月30日共纳入2409名儿童,排除后分析2405名;随机化前纳入964名,随机化后纳入1441名(意向性治疗)。

主要发现

  • 共发生104例死亡,其中91例发生在检测到低氧血症后48小时内。
  • 48小时死亡率随机化前为49/964(5.1%),随机化后为42/1440(2.9%)(校正OR 0.50,95%CI 0.27-0.91,p=0.023)。
  • 结果对长期趋势的替代参数化敏感;相对风险降低48.7%(95%CI 8.5-71.5),每挽救1例生命需治疗45例(95%CI 28-230)。
  • 氧疗使用从随机化前484/964(50.2%)增至随机化后1424/1441(98.8%)(p<0.0001)。
  • 不良事件在随机化前后相似,未被认为与干预相关;估计成本效果为每挽救一个伤残调整生命年25美元(6-505)。

临床怎么用

  • 作者认为太阳能供氧可作为中低收入国家应对氧不安全的解决方案之一进行推广,本研究可作为推广模式。

局限性

  • 结果对长期趋势的替代参数化敏感。
  • 研究未整体设盲。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Supplemental O2 is not always available at health facilities in low-income and middle-income countries (LMICs). Solar-powered O2 delivery can overcome gaps in O2 access, generating O2 independent of grid electricity. We hypothesized that installation of solar-powered O2 systems on the paediatrics ward of rural Ugandan hospitals would lead to a reduction in mortality among hypoxaemic children. METHODS: In this pragmatic, country-wide, stepped-wedge, cluster randomised controlled trial, solar-powered O2 systems (ie, photovoltaic cells, battery bank, and O2 concentrator) were sequentially installed at 20 rural health facilities in Uganda. Sites were selected for inclusion based on the following criteria: District Hospital or Health Centre IV with paediatric inpatient services; supplemental O2 on the paediatric ward was not available or was unreliable; and adequate space to install solar panels, a battery bank, and electrical wiring. Allocation concealment was achieved for sites up to 2 weeks before installation, but the study was not masked overall. Children younger than 5 years admitted to hospital with hypoxaemia and respiratory signs were included. The primary outcome was mortality within 48 h of detection of hypoxaemia. The statistical analysis used a linear mixed effects logistic regression model accounting for cluster as random effect and calendar time as fixed effect. The trial is registered at ClinicalTrials.gov, NCT03851783. FINDINGS: Between June 28, 2019, and Nov 30, 2021, 2409 children were enrolled across 20 hospitals and, after exclusions, 2405 children were analysed. 964 children were enrolled before site randomisation and 1441 children were enrolled after site randomisation (intention to treat). There were 104 deaths, 91 of which occurred within 48 h of detection of hypoxaemia. The 48 h mortality was 49 (5·1%) of 964 children before randomisation and 42 (2·9%) of 1440 (one individual did not have vital status documented at 48 h) after randomisation (adjusted odds ratio 0·50, 95% CI 0·27-0·91, p=0·023). Results were sensitive to alternative parameterisations of the secular trend. There was a relative risk reduction of 48·7% (95% CI 8·5-71·5), and a number needed to treat with solar-powered O2 of 45 (95% CI 28-230) to save one life. Use of O2 increased from 484 (50·2%) of 964 children before randomisation to 1424 (98·8%) of 1441 children after randomisation (p<0·0001). Adverse events were similar before and after randomisation and were not considered to be related to the intervention. The estimated cost-effectiveness was US$25 (6-505) per disability-adjusted life-year saved. INTERPRETATION: This stepped-wedge, cluster randomised controlled trial shows the mortality benefit of improving O2 access with solar-powered O2. This study could serve as a model for scale-up of solar-powered O2 as one solution to O2 insecurity in LMICs. FUNDING: Grand Challenges Canada and The Women and Children's Health Research Institute.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Conradi N, Opoka RO, Mian Q, et al. Solar-powered O2 delivery for the treatment of children with hypoxaemia in Uganda: a stepped-wedge, cluster randomised controlled trial. Lancet. 2024. PMID: 38367643. doi:10.1016/S0140-6736(23)02502-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。